CoChat

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary

The DOI matches its Crossref record; 123 of the 130 references it cites were found in a registry or an index.

Abstract

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a)…

Overview

Integrity signals

Registry

Crossref · 10.4158/cs-2020-0490

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 123 references

Research works printed but not linked: 4

  1. Sever, 2003, J Am Coll Cardiol., 361, 1149
  2. Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Cardiovasc Diabetol., 366, 1849
  3. 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, N Engl J Med., 102, 21
  4. Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page

Cited by

See all 248

Metadata

Authors
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L.
Affiliations
  • University of Miami (US)
  • University of California San Diego (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of California, Los Angeles (US)
  • University of Chicago (US)
  • Oregon Health & Science University (US)
  • Tulane University (US)
  • Baylor College of Medicine (US)
  • Oakland University (US)
  • University of California, San Francisco (US)
  • University of California, Irvine (US)
  • The Ohio State University Wexner Medical Center (US)
Corresponding author
Handelsman, Yehuda
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2020-10
Volume
26
Issue
10
Pages
1196-1224
ISSN
1530-891X (ISSN-L)
OpenAlex
W3095590613
Cited by
248
References
130
Citations by year
2026: 20 · 2025: 36 · 2024: 58 · 2023: 50 · 2022: 57 · 2021: 26 · 2020: 1
FWCI
30.59
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Endocrine Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
dyslipidemia management, atherosclerotic cardiovascular disease prevention, LDL cholesterol targets, high-intensity statin therapy, PCSK9 inhibitors, ezetimibe, colesevelam, bempedoic acid, triglyceride-lowering therapy, fibrates, omega-3 fatty acids, nicotinic acid, icosapent ethyl, lipoprotein(a), statin intolerance, lifestyle therapy, cardiovascular risk stratification
MeSH terms
Endocrinologists, Algorithms, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Risk Factors, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Consensus, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. https://app.cochat.ai/papers/10.4158/cs-2020-0490
The paper
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocrine Practice. https://doi.org/10.4158/cs-2020-0490

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.